Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsA.K. Ellis has participated in advisory boards for Abbvie, ALK-Abelló, AstraZeneca, Bausch Health, Circassia Ltd, GlaxoSmithKline, LEO Pharma, Johnson & Johnson, Merck, Miravo, Mylan, Novartis, Pediapharm and Pfizer, has been a speaker for ALK, Aralez, AstraZeneca, Bausch Health, Boehringer-Ingelheim, CACME, Meda, Medexus, Mylan, Merck, Novartis,, Pfizer, The ACADEMY, and Takeda. Her institution has received research grants from AstraZeneca, Bayer, LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron and Sanofi. She has also served as an independent consultant to Allergy Therapeutics, Bayer, LLC, Ora Inc., and Regeneron in the past. D. Mack has provided consultation and speaker services for Pfizer, Aimmune, Kaleo, Merck, Covis and Pediapharm, and has been part of an advisory board for Pfizer and Bausch Health. He sits on the editorial board for the Journal of Food Allergy and has served as an investigator for ALK-Abelló. R. Gagnon has served as a speaker and/or advisor for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi, and Shire, and Valeo Pharma, and served as an investigator for AstraZeneca, Amgen, Biocryst, DBV, GlaxoSmithKline, Green Cross Pharmaceuticals, Merck, Novartis, Pharvaris, Regeneron, Shire, Stallergenes, and Sanofi Genzyme/Regeneron. S. Gosain is an employee of PDCI Market Access Inc., which provided contracted services to ALK- Abelló A/S. E. Hammerby is an employee of ALK- Abelló A/S. Competing interests A.K. Ellis has participated in advisory boards for Abbvie, ALK-Abelló, AstraZeneca, Bausch Health, Circassia Ltd, GlaxoSmithKline, LEO Pharma, Johnson & Johnson, Merck, Miravo, Mylan, Novartis, Pediapharm and Pfizer, has been a speaker for ALK, Aralez, AstraZeneca, Bausch Health, Boehringer-Ingelheim, CACME, Meda, Medexus, Mylan, Merck, Novartis,, Pfizer, The ACADEMY, and Takeda. Her institution has received research grants from AstraZeneca, Bayer, LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron and Sanofi. She has also served as an independent consultant to Allergy Therapeutics, Bayer, LLC, Ora Inc., and Regeneron in the past. D. Mack has provided consultation and speaker services for Pfizer, Aimmune, Kaleo, Merck, Covis and Pediapharm, and has been part of an advisory board for Pfizer and Bausch Health. He sits on the editorial board for the Journal of Food Allergy and has served as an investigator for ALK-Abelló. R. Gagnon has served as a speaker and/or advisor for ALK-Abello, AstraZeneca, Bausch Health, CSL Behring, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi, and Shire, and Valeo Pharma, and served as an investigator for AstraZeneca, Amgen, Biocryst, DBV, GlaxoSmithKline, Green Cross Pharmaceuticals, Merck, Novartis, Pharvaris, Regeneron, Shire, Stallergenes, and Sanofi Genzyme/Regeneron. S. Gosain is an employee of PDCI Market Access Inc., which provided contracted services to ALK- Abelló A/S. E. Hammerby is an employee of ALK- Abelló A/S."

"Funding The analysis was funded by ALK- Abelló A/S, Hørsholm, Denmark. Medical writing and editorial assistance provided by Erin P. Scott, PhD, of Scott Medical Communications, LLC, were funded by ALK- Abelló A/S."